Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

CHIESI FARMACEUTICI S.P.A.

ClinicalTrials.gov lists CHIESI FARMACEUTICI S.P.A. as lead sponsor of 184 trials. It has 113 active development programs and 44 approved assets.

IT Manufacturer
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

20 0 2002 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 10 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 7 in 2026 and about 9 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 10 already registered with a 2026 start date: at the cutoff, 5 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.

Logo FDRMRZUSA, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.

This page covers CHIESI FARMACEUTICI S.P.A.: 184 lead-sponsored trials and 1 legal-entity registration. The parent company on record for CHIESI FARMACEUTICI S.P.A. is VALLINE S.R.L., which does not have its own page on this site.

Get the CHIESI FARMACEUTICI S.P.A. report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (78)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Asthma 70
Pulmonary Disease, Chronic Obstructive 66
Cerebral Small Vessel Diseases 13
Fabry Disease 13
Respiratory Distress Syndrome 9

Trials by start year as sponsor or collaborator (24)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 10
2025 9
2024 6
2023 8
2022 13
2021 15
2020 6
2019 10
2018 7
2017 14

Prediction, not a registry value: median of 30 months from start to primary completion across 10 trials still running at the 2026-10-09 snapshot; registered median of 11 months across 153 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (113)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Metreleptin Lipodystrophy Phase 3 2
Lamazym alpha-Mannosidosis Phase 3 6
Pegunigalsidase Alfa Cerebral Small Vessel Diseases Phase 3 4
Pegunigalsidase Alfa Fabry Disease Phase 3 4
Seretide Evohaler Asthma Phase 3 2

Approved assets (44)

Shown in this order: max phase first.

Approved assets
Drug Trials
Poractant Alfa 3
CHF1535 2
FOSTER 2
CHF5993 2
ENVARSUS 2

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
56% hit target (n=61) 33% on time (n=61)

Journals published in (150)

Shown in this order: most published in first.

Journals published in
Journal Publications
The European respiratory journal 24
The New England journal of medicine 20
Respiratory medicine 18
Respiratory research 18
International journal of chronic obstructive pulmonary disease 16

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
330 50 2025-12-23

FDA inspection record (1)

FDA inspection record
Latest classification Inspections
VAI 5

FDA import refusals (1)

FDA import refusals
Refused import lines Latest refusal
5 2020-05-15

Manufacturing and distribution sites (3)

Shown in this order: severity rank then name.

Manufacturing and distribution sites
Facility Location Regulators Member organization
Chiesi Farmaceutici S.p.A. Parma, IT EMA, FDA, Health Canada
Chiesi Farmaceutici S.p.A. Parma, IT EMA
CHIESI FARMACEUTICI S.P.A. PARMA, IT EMA

Organization relationships (7)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Icon Plc Uses vendor 3
Iqvia Holdings Inc. Uses vendor 2
Chiesi (Germany) Parent of 1
Chiesi (France) Parent of 1
Chiesi (United States) Parent of 1

Latest dated events (563)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-11-16 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-11 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10-27 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10-14 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (380)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
APOH Trial sponsor Named in trial inclusion criteria
APOH Trial sponsor Named in trial inclusion criteria
APOH Trial sponsor Named in trial inclusion criteria
APOH Trial sponsor Named in trial inclusion criteria
APOH Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.